Deal Tracker · Countries

Türkiye pharma deals

12 pharma deals involving Türkiye — companies based there or deals covering the market — tracked by EPT: distribution, joint ventures & licensing. Most active: Gen İlaç, Abdi İbrahim, Abdi Ibrahim Global Pharm & Accord Healthcare. Latest: EastPharma → Sanofi (M&A / Acquisition, 20 Oct 2026).

12
deals tracked
10
announced in 2026
$544.8m
disclosed value (5 deals)
25%
distribution, the top deal type
  • EPT has tracked 12 Türkiye pharma deals (2024–2026), 10 of them announced in 2026.
  • The most common structures are distribution (25%), joint ventures (17%) & licensing (17%).
  • Values were disclosed for 5 of 12 deals, totalling $544.8m; the largest is Faes Farma → SIFI ($310m, 2 Sept 2025).
  • The most active companies: Gen İlaç (3) & Abdi İbrahim (2).

Most active companies

Gen İlaç (3) · Abdi İbrahim (2)

Countries involved

Kazakhstan (3) · Azerbaijan (2) · China (2) · Italy (2) · Egypt (1) · Saudi Arabia (1)

Largest disclosed deals

Questions

How many Türkiye pharma deals has EPT tracked?
12 as of 20 Oct 2026, covering 2024–2026; 10 were announced in 2026. The most recent is EastPharma → Sanofi (M&A / Acquisition, 20 Oct 2026).
What types of Türkiye pharma deals are most common?
Distribution: 3 (25%); Joint venture: 2 (17%); Licensing: 2 (17%); M&A / Acquisition: 2 (17%).
Which companies are most active in Türkiye pharma deals?
Gen İlaç (3 deals), Abdi İbrahim (2 deals).
What is the largest disclosed Türkiye pharma deal?
Faes Farma → SIFI: $310m (M&A / Acquisition, 2 Sept 2025); Nobel İlaç → Nobel Almaty Pharmaceutical Factory: $84m (Technology transfer / Localization, 22 Jan 2026); Abdi İbrahim → Abdi Ibrahim Global Pharm: $83m (Technology transfer / Localization, 22 Jan 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)